



































ol)	 derivatives	 via	 a	 one‐pot	 pseudo	 five‐component	 reaction	 of	 phenyl	 hydrazine,	 ethyl
acetoacetate	 and	 aldehydes	 in	 acetic	 acid	 is	 reported.	 The	 prepared	 compounds	 were
characterized	by	elemental	analyses	and	spectral	data.	Some	of	the	synthesized	compounds
were	 screened	 for	 their	 antioxidant	 activity	 using	2,2'‐azino‐bis(3‐ethyl	 benzothiazoline‐6‐
sulfonic	 acid	 (ABTS)	 method;	 all	 the	 investigated	 compounds	 showed	 similar	 and	 higher















considered	to	play	a	pivotal	 role	 in	 the	pathogenesis	of	aging	
and	 degenerative	 diseases	 [1‐3].	 In	 order	 to	 cope	 with	 an	
excess	of	free	radicals	produced	upon	oxidative	stress,	human	
bodies	 have	 developed	 sophisticated	 mechanisms	 for	 main‐
taining	 redox	 homeostasis.	 These	 protective	 mechanisms	
include	scavenging	or	detoxification	of	reactive	oxygen	species	
(ROS),	 blocking	 ROS	 production,	 sequestration	 of	 transition	
metals,	 as	 well	 as	 enzymatic	 and	 non‐enzymatic	 antioxidant	
defenses	produced	 in	 the	body,	 that	 is,	 endogenous	 [4,5]	and	
others	supplied	with	the	diet,	namely,	exogenous	ones.	Among	
them,	dietary	polyphenols	have	been	widely	studied	 for	 their	
strong	 antioxidant	 capacities	 and	 other	 properties	 by	 which	
cell	functions	are	regulated	[6].		






have	 a	 broad	 spectrum	 of	 approved	 biological	 activity,	 being	
used	 as	 anti‐inflammatory	 [9],	 gastric	 secretion	 stimulatory	
[10],	 antidepressant	 [11],	 antibacterial	 [12],	 and	 antifilarial	
agents	[13].	Moreover,	these	compounds	have	been	applied	as	
fungicides	 [14],	 pesticides	 [15],	 insecticides	 [16],	 dyestuffs	
[17],	and	chelating	as	well	as	extracting	reagents	for	different	
metal	ions	[18].	
Numerous	 synthetic	methods	have	 been	 reported	 for	 the	
preparation	of	4,4'‐(aryl‐methylene)bis(3‐methyl‐1‐phenyl‐
1H‐pyrazol‐5‐ol)	 under	 classical	 or	 modified	 conditions	 [19‐
31].	 However,	 some	 of	 these	methods	 suffer	 from	 expensive	
reagents,	 low	yield,	 prolonged	 reaction	 time	 and	 use	 of	 toxic	
organic	 solvents,	 and	 tedious	 workup	 procedures.	 Thus,	 a	
search	for	new	reagents	and	the	development	of	new	methods	
are	still	of	practical	 importance.	 In	 this	regard,	we	decided	to	
explore	the	possibility	of	synthesizing	4,4'‐(aryl‐methylene)bis	
(3‐methyl‐1‐phenyl‐pyrazol‐5‐ol)	 via	 a	 novel,	 one‐pot,	 multi‐
component	condensation	of	phenyl	hydrazine	(2	equiv.),	ethyl	
acetoacetate	 (2	 equiv.)	 and	 aromatic	 aldehydes	 (1	 equiv.)	 in	









Product	 Ar	 Time	(hr)	 Yield	(%)	a	
4a	 Phenyl	 7 77	
4b	 4‐Methoxyphenyl 6 83	
4c	 4‐Chlorophenyl	 6 81	
4d	 2‐Thienyl	 6	 74	
4e	 4‐Bromophenyl	 7 77	
4f	 4‐Florophenyl	 6 83	










All	 melting	 points	 are	 recorded	 on	 Gallenkamp	 electric	
melting	point	apparatus	and	are	uncorrected.	The	IR	spectra	ν	
(cm‐1)	 (KBr)	 were	 recorded	 on	 a	 Perkin	 Elmer	 Infrared	
Spectrophotometer	 Model	 157.	 The	 1H	 NMR	 spectra	 were	
obtained	on	a	JEOL	Spectrophotometer	at	500	MHz,	using	TMS	
as	 an	 internal	 reference	 and	 DMSO‐d6	 as	 solvent	 and	 were	
carried	out	in	the	National	Research	Center,	Dokki,	Giza,	Egypt.	





Typical	 procedure	 for	 the	 synthesis	 of	 4,4'‐(substituted‐
methylene)bis(3‐methyl‐1‐phenyl‐1H‐pyrazol‐5‐ol)	 (4a‐g):	 A	
mixture	 of	 phenylhydrazine	 (2.1	 g,	 20	 mmol),	 ethyl	 aceto‐




















Yield:	 83%.	 M.p.:	 163‐165	 °C	 [Lit.	 [33],	 160‐161	 °C].	 FT‐IR	
(KBr,	ν,	cm‐1):	3138	(NH),	3059	(CHarom.),	3035	(br,	OH),	1578	














zol‐5‐ol)	 (4d):	Reaction	 time:	 6	h.	 Color:	White	 crystal.	 Yield:	
74%.	M.p.:	 289‐190	 °C	 [Lit.	 [34],	 190‐192	 °C].	 FT‐IR	 (KBr,	 ν,	
cm‐1):	3080	(br,	OH),	1595	(C=N).	1H	NMR	(500	MHz,	DMSO‐d6,	






Yield:	 77%.	 M.p.:	 185‐186	 °C	 [Lit.	 [35],	 183‐184	 °C].	 FT‐IR	
(KBr,	ν,	cm‐1):	3062	(br,	OH),	1595	(C=N),	602	(C‐Br).	1H	NMR	






Yield:	 83%.	 M.p.:	 180‐181	 °C	 [Lit.	 [35],	 182‐184	 °C].	 FT‐IR	
(KBr,	 ν,	 cm‐1):	 3065	 (br,	OH),	1599	 (C=N),	 753(C‐F).	 1H	NMR	
(500	MHz,	DMSO‐d6,	 δ,	 ppm):	 2.33	 (s,	 6H,	 2CH3),	 5.34	 (s,	 1H,	
CH‐C6H4F),	 7.18‐7.71	 (m,	 14H,	ArH),	 11.43	 (s,	 1H,	OH),	 13.91	




Yield:	 81%.	 M.p.:	 218‐220	 °C	 [Lit.	 [36],	 219‐220	 °C].	 FT‐IR	












ABTS	 [2,2'‐azino‐bis(3‐ethyl	 benzothiazoline‐6‐sulfonic	 acid)]	
was	prepared	by	reaction	of	ABTS	(60	mL)	with	MnO2	(3	mL,	
25	mg/mL)	 in	 5	mL	 aqueous	 buffer	 solution	 (pH	 =	 7).	 After	
shaking	the	solution	for	a	few	minutes,	it	was	centrifuged	and	





of	 20	 mL	 of	 1	 mg/mL	 solution	 of	 the	 tested	 sample	 in	
spectroscopic	 grade	 MeOH:Buffer	 (1:1,	 v:v)	 to	 the	 ABTS	























To	 the	 reaction	mixtures	 in	 a	 final	 volume	of	1.0	mL,	 the	
following	 reagents	 at	 the	 final	 concentrations	 stated	 were	
added:	 DNA	 (0.2	 mg/mL),	 bleomycin	 (0.05	 mg/mL),	 FeCl3	
(0.025	mM),	magnesium	chloride	(5	mM),	KH2PO4/KOH	buffer	
pH	 =	 7.0	 (30	 mM)	 and	 ascorbic	 acid	 (0.24	 mM)	 or	 the	 test	
fractions	 diluted	 in	 MeOH	 to	 give	 a	 concentration	 of	 (0.1	
mg/mL).	 The	 reaction	 mixtures	 were	 incubated	 in	 a	 water‐
bath	at	37	°C	for	1	h.	At	 the	end	of	 the	 incubation	period,	0.1	
mL	 of	 ethylenediaminetetraacetic	 acid	 (EDTA)	 (0.1	 M)	 was	












The	 synthetic	 strategies	 adopted	 to	 obtain	 the	 target	
compounds	 are	 depicted	 in	 Scheme	 1.	Multicomponent	 reac‐
tions	(MCR)	of	phenyl	hydrazine	hydrate	 (1)	(2	equiv.),	ethyl	
acetoacetate	 (2)	 (2	 equiv.)	 and	 aldehydes	 (3)	 (1	 equiv.)	 in	
acetic	acid	(50%)	afforded	4,4'‐(aryl‐methylene)‐bis(3‐methyl‐
1‐phenyl‐1H‐pyrazol‐5‐ol)s	(4)	(Scheme	1).	
The	 possible	 mechanism	 for	 the	 synthesis	 of	 compound	
4a‐g	 is	 representing	 in	Scheme	2.	Protonation	of	ethyl	aceto‐
acetate	 (EAA)	2	 by	 acetic	 acid	 generates	 the	 enol	 I.	 electro‐
philic	attraction	of	phenylhydrazine	1	 to	the	enol	(I)	afforded	
the	ammonium	salt	(II),	hydronium	ion	transfer	take	place	to	
form	 the	 oxonium	 ion	 (III).	 Cyclization	 of	 compound	 III	
afforded	the	pyrazolium	ion	(IV)	which	loss	proton	to	convert	
into	 pyrazole	 (V).	 Protonation	 of	 compound	V	by	 acetic	 acid	
generates	 the	 enol	 (VI)	 which	 reacts	 with	 the	 aldehydic	
carbonyl	 to	 form	 six‐membered	 cyclic	 transition	 state	 (VII)	
and	 increases	 the	 electrophilicity	 of	 the	 aldehyde	 carbonyl	
group	and	makes	it	more	susceptible	to	nucleophilic	attack	in	
an	intramolecular	fashion	to	form	the	intermediate	(VIII).	The	
intermediate	 VIII	 subsequently	 abstracts	 the	 proton	 from	
acetic	 acid	and	generates	 the	 enolate	 aldol	 cation	 (IX)	which	
interact	with	 compound	V	 to	 generate	 the	 enol	 form	 (VI)	 to	
complete	 the	 catalytic	 cycle.	 The	 aldol	 X	 on	 dehydration	
results	in	the	formation	of	4‐arylidene‐3‐methyl‐1‐phenyl‐1H‐
pyrazol‐5(4H)‐one	(XI)	which	reacted	with	acetic	acid	to	form	
the	 cation	 XII,	 condensation	 with	 compound	 VI	 to	 form	 the	
corresponding	 bis‐enolate	 cation	 (XIII),	 which	 subsequently	
loss	 proton	 and	 form	 the	 target	 of	 compound	 4a‐g.	 The	
products	4a‐g	were	characterized	by	IR	and	1H	NMR	analysis.	
For	 example,	 the	 1H	NMR	 spectra	 of	 compound	4b	 indicated	
the	presence	of	three	singlet	signals	at	δ	2.46,	3.85,	4.89	ppm	
due	 to	 2CH3,	 OCH3	 and	 arylmethylene	 protons,	 respectively,	
and	 a	 broad	 two	 singlet	 signal	 at	 δ	 12.62	 and	 13.85	 ppm	
reminiscent	 of	 two	 enolisable	 OH	 groups.	 The	 IR	 spectra	 of	







The	 synthesized	 compounds	 were	 screened	 for	 their	
antioxidant	 activity	 using	 ABTS	 method	 which	 reported	 by	
Lissi	et	al.	 [37].	The	antioxidant	activity	assay	employed	here	
is	 one	 of	 the	 several	 assays	 that	 depends	 on	 measuring	 the	
consumption	of	stable	free	radicals	i.e.	evaluate	the	free	radical	




XH	+	Y'	→	X'	+	YH	 	 	 	 	 (2)	
	
Total	 antioxidant	 potential	 of	 resinous	 exudates	 from	
Heliotropium	species,	and	a	comparison	of	the	ABTS	methods.	
The	rate	and/or	the	extent	of	the	process	measured	in	terms	of	
the	 decrease	 in	 X'	 concentration,	 would	 be	 related	 to	 the	
ability	 of	 the	 added	 compounds	 to	 trap	 free	 radicals.	 The	
decrease	 in	 color	 intensity	 of	 the	 free	 radical	 solution	due	 to	











The	bleomycin	 is	a	 family	of	glycopeptide	antibiotics	 that	
was	used	routinely	as	antitumor	agents.	The	bleomycin	assay	
was	 adopted	 for	 assessing	 the	 pro‐oxidant	 effects	 of	 food	
antioxidants.	 The	 antitumor	 antibiotic	 bleomycin	 binds	 iron	
ions	and	DNA.	The	bleomycin	iron	complex	degrades	DNA	that,	
upon	 heating	 with	 thiobarbituric	 acid	 (TBA),	 yields	 a	 pink	
chromogen.	 Upon	 the	 addition	 of	 suitable	 reducing	 agents	
antioxidants	 compete	 with	 DNA	 and	 diminish	 chromogen	
formation	[38‐41].		
The	 protective	 activity	 against	 DNA	 damage	 induced	 by	
bleomycin	 iron	 complex	was	 examined	 in	 order	 to	 show	 the	
action	 of	 the	 investigated	 compounds.	 The	 results	 in	 Table	 2	
showed	 that	 compounds	 all	 the	 investigated	 compounds	
showed	 similar	 and	 higher	 antioxidant	 activity	 than	 ascorbic	
acid	 and	 exhibited	 high	 protection	 against	 DNA	 damage	
induced	 by	 the	 bleomycin	 iron	 complex,	 thus,	 diminishing	



























































































































































By	 comparing	 the	 results	 obtained	 for	 the	 antioxidant	
properties	of	the	compounds	reported	in	this	study	with	their	
structures,	 the	 following	 structure	 activity	 relationships	
(SAR's)	were	postulated	(Scheme	3).	
(i) Pyrazole	V	 (Scheme	 3)	 is	 more	 potent	 than	 ascorbic	
acid	 which	 may	 be	 attributed	 to	 the	 replacement	 of	

































(ii) All	 the	 investigated	 compounds	 showed	 similar	 and	














using	 acetic	 acid.	 The	 short	 reaction	 times,	 one‐pot,	 multi‐
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